跳至主要内容
临床试验/EUCTR2005-002741-39-ES
EUCTR2005-002741-39-ES进行中(未招募)1 期

A prospective, controlled, randomized, patient and evaluator blinded study to evaluate pain and further disabling complications in patients undergoing Lichtenstein technique for primary inguinal hernia repair by fixing the mesh with TISSUCOL/TISSEEL fibrin sealant versus sutures.

Pr Giampiero CAMPANELLI - Ospedale Maggiore Policlinico, Padiglione Beretta Est0 个研究点目标入组 328 人开始时间: 2006年1月18日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
328

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • 1. Written signed informed consent obtained from the subject prior to participation in the study.
  • 2. Active males over the age of 18 years and till 70 years. Active is defined by having normal daily activities.
  • 3. Experiencing an uncomplicated unilateral primary inguinal hernia.
  • 4. Subjects eligible for elective inguinal hernia repair using Lichtenstein technique.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1. Recurrent, bilateral, scrotal, incarcerated or femoral hernias.
  • 2. Hernia types L3 and M3 according the European Hernia Society classification assessed pre or intra-operatively
  • 3. BMI equal or more than 35
  • 4. Concomitant abdominal surgery
  • 5. Ongoing long term analgesic or steroid treatment
  • 6. Patients under Clopidogrel or Warfarin (can be switched to LMW sub-cutaneous heparin)
  • 7. Known abuse of alcohol or drugs
  • 8. Liver cirrhosis (Child C)
  • 9. Hypersensitivity to bovine aprotinin
  • 10. Known immunodeficiency
  • 11. Severely compromised physical or psychological health, that in the investigator’s opinion will affect patient’s compliance
  • 12. Concurrently participating in another clinical trial and having received another investigational drug or device within the last 30 days

研究者

发起方
Pr Giampiero CAMPANELLI - Ospedale Maggiore Policlinico, Padiglione Beretta Est

相似试验

进行中(未招募)
不适用
A prospective, controlled, randomized, patient and evaluator blinded study to evaluate pain and further disabling complications in patients undergoing Lichtenstein technique for primary inguinal hernia repair by fixing the mesh with TISSUCOL/TISSEEL fibrin sealant versus sutures. - TIMELI 001nilateral, uncomplicated primary inguinal hernia repairClassification code 10022020
EUCTR2005-002741-39-DKniversità di Milano, Dipartimento di Scienze Chirurgiche, Ospedale Maggiore Policlinico, Padiglione328
进行中(未招募)
不适用
A prospective, controlled, randomized, patient and evaluator blinded study to evaluate pain and further disabling complications in patients undergoing Lichtenstein technique for primary inguinal hernia repair by fixing the mesh with Tissucol/Tisseel fibrin sealant versus sutures - TI.ME.LI. studySubjects requiring a unilateral tension-free hernioplasty by Lichtenstein technique.MedDRA version: 6.1Level: PTClassification code 10022020
EUCTR2005-002741-39-ITOSPEDALE MAGGIORE DI MILANO IRCCS328
进行中(未招募)
1 期
A prospective, controlled, randomized, patient and evaluator blinded study to evaluate pain and further disabling complications in patients undergoing Lichtenstein technique for primary inguinal hernia repair by fixing the mesh with fibrin sealant versus sutures. - TIMILI 001
EUCTR2005-002741-39-GBProf. Giampiero CAMPANELLI328
进行中(未招募)
4 期
A comparative study to evaluate the efficacy and safety of Troxipide (100 mg) and Rabeprazole (20 mg) alone and in combination in patients of Acid peptic disorders.
CTRI/2013/09/003944Government Medical College Hospital100
进行中(未招募)
1 期
Efficacy of nebulized 4.2% sodium-bicarbonate in COVID-19 pneumoniasevere COVID-19 pneumonia requires invasive ventillatory supportMedDRA version: 23.1Level: LLTClassification code 10084564Term: SARS-CoV-2 pneumoniaSystem Organ Class: 100000004862
EUCTR2021-001665-20-HUSemmelweis University Department of Oralbiology200